Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-4 (of 4 Records) |
Query Trace: Grigoryan A[original query] |
---|
Multicountry analysis of spectrum of clinical manifestations of children <5 years of age hospitalized with diarrhea
Murray J , Soenarto SY , Mulyani NS , Wijesinghe PS , Mpabalwani EM , Simwaka JC , Matapo B , Mwenda JM , Sahakyan G , Grigoryan S , Vanyan A , Khactatryan S , Sanwogou J , Helena de Oliveira L , Rey-Benito G , Kang G , Serhan F , Tate JE , Aliabadi N , Cohen AL . Emerg Infect Dis 2019 25 (12) 2253-2256 After introduction of rotavirus vaccine, other pathogens might become leading causes of hospitalizations for severe diarrhea among children <5 years of age. Our study in 33 hospitals in 7 countries found acute gastroenteritis accounted for most (84%) reported hospitalizations of children with diarrhea. Bloody and persistent diarrhea each accounted for <1%. |
Impact and effectiveness of monovalent rotavirus vaccine in Armenian children
Sahakyan G , Grigoryan S , Wasley A , Mosina L , Sargsyan S , Asoyan A , Gevorgyan Z , Kocharyan K , Avagyan T , Lopman B , Vanyan A , Khactatryan S , Parashar UD , Cortese MM . Clin Infect Dis 2016 62 S147-S154 Background. The Republic of Armenia was 1 of the 2 earliest countries in the Newly Independent States to introduce rotavirus vaccine into its national immunization program to reduce the burden of rotavirus disease (documented to cause 38% of acute gastroenteritis hospitalizations [AGE] among children aged <5 years). In November 2012, RV1 (Rotarix) was introduced for Armenian infants at ages 6 and 12 weeks. Methods. The established active surveillance system at 2 hospitals in the capital, Yerevan, whereby children aged <5 years hospitalized for AGE have stool sample tested for rotavirus antigen, was used to assess trends in rotavirus hospitalizations. Immunization records on children enrolled after vaccine introduction were obtained from clinics, and vaccine effectiveness (VE) was estimated using children with AGE who test negative for rotavirus as controls for the rotavirus-positive cases. Results. Among infants, rotavirus hospitalizations were reduced by 48% within the first year after introduction, and by >=75% in years 2 and 3 following introduction. Reductions of >=30% in other young children too old to have been vaccinated suggest additional benefit through indirect protection; overall in year 3, rotavirus hospitalizations were reduced by 69% among children aged <5 years. The overall VE of 2 RV1 doses in protecting against rotavirus hospitalization (any severity) was 62% (95% confidence interval [CI], 36%-77%) among children aged 6-23 months; 68% (95% CI, 24%-86%) among those aged 6-11 months, and 60% (95% CI, 20%-80%) in children aged 12-23 months. Against more severe rotavirus disease, VE was 79% (95% CI, 55%-90%) and similarly high in both age groups. Conclusions. RV1 is effective in young Armenian children and substantially reduced rotavirus hospitalizations shortly after introduction. |
Summary of notifiable diseases - United States, 2012
Adams DA , Jajosky RA , Ajani U , Kriseman J , Sharp P , Onwen DH , Schley AW , Anderson WJ , Grigoryan A , Aranas AE , Wodajo MS , Abellera JP . MMWR Morb Mortal Wkly Rep 2014 61 (53) 1-121 The Summary of Notifiable Diseases - United States, 2012 contains the official statistics, in tabular and graphic form, for the reported occurrence of nationally notifiable infectious diseases in the United States for 2012. Unless otherwise noted, the data are final totals for 2012 reported as of June 30, 2013. These statistics are collected and compiled from reports sent by state health departments and territories to the National Notifiable Diseases Surveillance System (NNDSS), which is operated by CDC in collaboration with the Council of State and Territorial Epidemiologists (CSTE). |
Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients
Ison MG , Llata E , Conover CS , Friedewald JJ , Gerber SI , Grigoryan A , Heneine W , Millis JM , Simon DM , Teo CG , Kuehnert MJ . Am J Transplant 2011 11 (6) 1218-1225 In 2007, a previously uninfected kidney transplant recipient tested positive for human immunodeficiency virus type 1 (HIV) and hepatitis C virus (HCV) infection. Clinical information of the organ donor and the recipients was collected by medical record review. Sera from recipients and donor were tested for serologic and nucleic acid-based markers of HIV and HCV infection, and isolates were compared for genetic relatedness. Routine donor serologic screening for HIV and HCV infection was negative; the donor's only known risk factor for HIV was having sex with another man. Four organs (two kidneys, liver and heart) were transplanted to four recipients. Nucleic acid testing (NAT) of donor sera and posttransplant sera from all recipients were positive for HIV and HCV. HIV nucleotide sequences were indistinguishable between the donor and four recipients, and HCV subgenomic sequences clustered closely together. Two patients subsequently died and the transplanted organs failed in the other two patients. This is the first recognized cotransmission of HIV and HCV from an organ donor to transplant recipients. Routine posttransplant HIV and HCV serological testing and NAT of recipients of organs from donors with suspected risk factors should be considered as routine practice. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure